Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
In Reply: We suspect that many physicians share
the opinion of Drs Perret-Guillaume and Wahl that the utility of warfarin
therapy that we used seemed too high, since physicians tend to be more averse
to warfarin therapy than are patients with atrial fibrillation.1 As
physicians, we need to take care that our own preferences (or our personal
desire to avoid monitoring warfarin) do not usurp our patients’ preferences.
O’Brien CL, Gage BF. Cost-effectiveness of Ximelagatran for Stroke Prevention—Reply. JAMA. 2005;293(23):2860-2861. doi:10.1001/jama.293.23.2861-a